Abiraterone - CYP17 inhibitor Abiraterone (CB-7598). CAS# 154229-19-3 one Demethylase Ledipasvir shows good half-lives (rat

Ledipasvir shows good half-lives (rat 1

InChiKey: NOQGZXFMHARMLW-UHFFFAOYSA-N

PubMed PMID: 29193663

is activated upon DNA damage and plays a key role in repairing double-stranded DNA breaks via the DNA nonhomologous end joining (NHEJ) pathway

Abiraterone - CYP17 inhibitor Abiraterone (CB-7598). CAS# 154229-19-3 one Demethylase Ledipasvir shows good half-lives (ratAbiraterone, CAS No. 154229 19 3, is the first in class potent and selective CYP17 (cytochrome P450 17alpha hydroxylase 17, 20 lyase) inhibitor with IC50 ~4 nM. It was approved by US FDA in 2011 to treat castration resistant prostate cancer. As prostate cancer cells proliferate in response to androgen steroids, CYP17 inhibition is a new strategy to prevent androgen synthesis and treat lethal metastatic prostate cancer. In recent Nature publication,